Related Experiment Video
Updated: Apr 12, 2026
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Spatial genomic heterogeneity within localized, multifocal prostate cancer
Paul C Boutros1, Michael Fraser2, Nicholas J Harding3
11] Ontario Institute for Cancer Research, Toronto, Ontario, Canada. [2] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. [3] Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
This study reveals significant genomic differences within multifocal prostate tumors, identifying MYCL amplification as a key factor. These findings highlight tumor evolution and can aid in developing new prognostic biomarkers.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Prostate cancer exhibits multifocality and spatial heterogeneity.
- Understanding intraprostatic genomic variation is crucial for targeted therapies and prognosis.
Purpose of the Study:
- To perform a detailed molecular analysis of spatial heterogeneity in clinically localized, multifocal prostate cancer.
- To identify novel oncogenes or tumor suppressors contributing to prostate cancer progression.
Main Methods:
- Copy number aberration (CNA) profiling of 74 patients with Gleason score 7 index tumors.
- Whole-genome sequencing of 23 distinct tumor regions from 5 patients to assess focal genomics.
- Analysis of single-nucleotide variants (SNVs), CNAs, and genomic rearrangements.
Main Results:
- Multifocal prostate tumors display significant heterogeneity in SNVs, CNAs, and genomic rearrangements.
- A recurrent amplification of MYCL was identified, associated with TP53 deletion.
- Evidence of divergent tumor evolution and independent clonal origins was observed.
Conclusions:
- Intraprostatic genomic heterogeneity is a key feature of multifocal prostate cancer.
- MYCL amplification and TP53 deletion are significant molecular events.
- Genomic data can inform the development of prognostic biomarkers for personalized treatment.
